Pembrolizumab with trastuzumab and chemotherapy-advanced or metastatic gastric or gastroesophageal junction adenocarcinomas with surexpression of HER2 and CPS ≥1

Bull Cancer. 2023 Dec 8:S0007-4551(23)00439-3. doi: 10.1016/j.bulcan.2023.11.004. Online ahead of print.NO ABSTRACTPMID:38071114 | DOI:10.1016/j.bulcan.2023.11.004

Source: Bulletin du Cancer - December 9, 2023 Category: Cancer & Oncology Authors: In ès Lévêque El éonore Spitzer Source Type: research